Abstract
Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. In recent years, there are significant progresses in our understanding of the underlying mechanisms and the potential therapeutic implications. Biochemical and molecular studies suggest several possible mechanisms by which this metabolic alteration may evolve during cancer development. These mechanisms include mitochondrial defects and malfunction, adaptation to hypoxic tumor microenvironment, oncogenic signaling, and abnormal expression of metabolic enzymes. Importantly, the increased dependence of cancer cells on glycolytic pathway for ATP generation provides a biochemical basis for the design of therapeutic strategies to preferentially kill cancer cells by pharmacological inhibition of glycolysis. Several small molecules have emerged that exhibit promising anticancer activity in vitro and in vivo, as single agent or in combination with other therapeutic modalities. The glycolytic inhibitors are particularly effective against cancer cells with mitochondrial defects or under hypoxic conditions, which are frequently associated with cellular resistance to conventional anticancer drugs and radiation therapy. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers and hypoxia is present in most tumor microenvironment, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1209597/MediaObjects/41388_2006_Article_BF1209597_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fsj.onc.1209597/MediaObjects/41388_2006_Article_BF1209597_Fig2_HTML.jpg)
Similar content being viewed by others
References
Arora KK, Fanciulli M, Pedersen PL . (1990). J Biol Chem 265: 6481–6488.
Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG et al. (2001). Lancet 357: 1181–1182.
Baumann M, Brand K . (1988). Cancer Res 48: 7018–7021.
Baumann M, Kappl A, Lang T, Brand K, Siegfried W, Paterok E . (1990). Cancer Investig 8: 351–356.
Bayley JP, Devilee P, Taschner PE . (2005). BMC Med Genet 6: 39–44.
Beutler E, West C, Britton HA, Harris J, Forman L . (1997). Blood Cells Mol Dis 23: 402–409.
Biaglow JE, Cerniglia G, Tuttle S, Bakanauskas V, Stevens C, McKenna G . (1997). Biochem Biophys Res Commun 235: 739–742.
Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y . (2005). Cancer Res 65: 999–1006.
Board M, Colquhoun A, Newsholme E, High A . (1995). Cancer Res 55: 3278–3285.
Bolin DC, Carlton WW . (1996). Vet Hum Toxicol 38: 85–88.
Boren J, Cascante M, Marin S, ComÃn-Anduix B, Centelles JJ, Lim S et al. (2001). J Biol Chem 276: 37747–37753.
Bork P, Sander C, Valencia A . (1993). Prot Sci 2: 31–40.
Boros LG, Bassilian S, Lim S, Lee WN . (2001). Pancreas 22: 1–7.
Brahimi-Horn MC, Pouyssegur J . (2005). Int Rev Cytol 242: 157–213.
Briasoulis E, Pavlidis N, Terret C, Bauer J, Fiedler W, Schoffski P et al. (2003). Eur J Cancer 39: 2334–2340.
Brown J . (1962). Metabolism 11: 1098–1112.
Bryson JM, Coy PE, Gottlob K, Hay N, Robey RB . (2002). J Biol Chem 277: 11392–11400.
Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S et al. (1998). Clin Cancer Res 4: 117–130.
Burgering BM, Coffer PJ . (1995). Nature 376: 599–602.
Bustamante E, Pedersen PL . (1977). Proc Natl Acad Sci USA 74: 3735–3739.
Cárdenas ML, Cornish-Bowden A, Ureta T . (1998). Biochim Biophys Acta 1401: 242–264.
Carew JS, Huang P . (2002). Mol Cancer 1: 9–20.
Carew JS, Zhou Y, Albitar M, Carew JD, Keating MJ, Huang P . (2003). Leukemia 17: 1437–1447.
Cattaneo A, Biocca S, Corvaja N, Calissano P . (1985). Exp Cell Res 161: 130–140.
Chen JZ, Kadlubar FF . (2004). J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 22: 1–12.
Chuang DM, Hough C, Senatorov VV . (2005). Annu Rev Pharmacol Toxicol 45: 269–290.
Comin-Anduix B, Boren J, Martinez S, Moro C, Centelles JJ, Trebukhina R et al. (2001). Eur J Biochem 268: 4177–4182.
Coy JF, Dressler D, Wilde J, Schubert P . (2005). Clin Lab 51: 257–273.
Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM et al. (2003). Nature 424: 952–956.
Dastoor Z, Dreyer JL . (2001). J Cell Sci 114: 1643–1653.
De Lena M, Lorusso V, Latorre A, Fanizza G, Gargano G, Caporusso L et al. (2001). Eur J Cancer 37: 364–368.
Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH . (1997). J Biol Chem 272: 17269–17275.
Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A, Cognetti F . (2003). Drugs Today (Barc) 39: 157–174.
Dollner R, Dietz A, Kopun M, Helbig M, Wallner F, Granzow C . (2004). Anticancer Res 24: 2947–2951.
Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al. (2004). Cancer Res 64: 3892–3899.
El-Zarruk AA, van den Berg HW . (1999). Cancer Lett 142: 185–193.
Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A . (2000). FEBS Lett 473: 47–52.
Filella X, Molina R, Jo J, Mas E, Ballesta AM . (1991). Tumour Biol 12: 360–367.
Flier JS, Mueckler MM, Usher P, Lodish HF . (1987). Science 235: 1492–1495.
Floridi A, Bruno T, Miccadei S, Fanciulli M, Federico A, Paggi MG . (1998). Biochem Pharmacol 56: 841–849.
Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C . (1981). J Natl Cancer Inst 66: 497–499.
Ford WC . (2006). Hum Reprod Update 12: 269–274.
Funasaka T, Haga A, Raz A, Nagase H . (2001). Biochem Biophys Res Commun 285: 118–128.
Funasaka T, Haga A, Raz A, Nagase H . (2002). Int J Cancer 101: 217–223.
Garg AK, Buchholz TA, Aggarwal BB . (2005). Antioxid Redox Signal 7: 1630–1647.
Gatenby RA, Gillies RJ . (2004). Nat Rev Cancer 4: 891–899.
Geschwind JF, Georgiades CS, Ko YH, Pedersen PL . (2004). Expert Rev Anticancer Ther 4: 449–457.
Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL . (2002). Cancer Res 62: 3909–3913.
Giaccone G, Smit EF, de Jonge M, Dansin E, Briasoulis E, Ardizzoni A et al. (2004). Eur J Cancer 40: 667–672.
Golshani-Hebroni SG, Bessman SP . (1997). J Bioenerg Biomembr 29: 331–338.
Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N . (2001). Genes Dev 15: 1406–1418.
Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ . (2004). Clin Cancer Res 10: 6661–6668.
Grosse F, Nasheuer HP, Scholtissek S, Schomburg U . (1986). Eur J Biochem 160: 459–467.
Harrison RA . (1974). Anal Biochem 61: 500–507.
Herrero P, Galindez J, Ruiz N, Martinez-Campa C, Moreno F . (1995). Yeast 11: 137–144.
Hirono Y, Fushida S, Yonemura Y, Yamamoto H, Watanabe H, Raz A . (1996). Br J Cancer 74: 2003–2007.
Ishitani R, Chuang DM . (1996). Proc Natl Acad Sci USA 93: 9937–9941.
Izyumov DS, Avetisyan AV, Pletjushkina OY, Sakharov DV, Wirtz KW, Chernyak BV et al. (2004). Biochim Biophys Acta 1658: 141–147.
Jelks KB, Miller MG . (2001). Toxicol Sci 62: 115–123.
Jones AR, Cooper TG . (1997). Xenobiotica 27: 711–721.
Kang HT, Hwang ES . (2005). Life Sci 78: 1392–1399.
Karnauskas R, Niu Q, Talapatra S, Plas DR, Greene ME, Crispino JD et al. (2003). Oncogene 22: 688–698.
Kim SU, Wenger BS . (1973). Acta Neuropathol (Berl) 26: 259–264.
Ko YH, Pedersen PL, Geschwind JF . (2001). Cancer Lett 173: 83–91.
Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS et al. (2004). Biochem Biophys Res Commun 324: 269–275.
Kohn AD, Summers SA, Birnbaum MJ, Roth RA . (1996). J Biol Chem 271: 31372–31378.
Koutcher JA, Alfieri AA, Stolfi RL, Devitt ML, Colofiore JR, Nord LD et al. (1993). Cancer Res 53: 3518–3523.
Layzer RB, Rowland LP, Bank WJ . (1969). J Biol Chem 244: 3823–3831.
Ledoux S, Yang R, Friedlander G, Laouari D . (2003). Cancer Res 63: 7284–7290.
Li C, Xiao Z, Chen Z, Zhang X, Li J, Wu X et al. (2006). Proteomics 6: 547–558.
Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH . (1998). Nutr Cancer 31: 184–191.
Lieberthal W, Menza SA, Levine JS . (1998). Am J Physiol Renal Physiol 274: F315–F327.
Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chiang PK et al. (1986). Proc Natl Acad Sci USA 83: 3302–3306.
Little E, Ramakrishnan M, Roy B, Gazit G, Lee AS . (1994). Crit Rev Eukaryotic Gene Expression 4: 1–18.
Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ . (2001). Biochemistry 40: 5542–5547.
Liu H, Savaraj N, Priebe W, Lampidis TJ . (2002). Biochem Pharmacol 64: 1745–1751.
Lynch RM, Fogarty KE, Fay FS . (1991). J Cell Biol 112: 385–395.
Maher JC, Krishan A, Lampidis TJ . (2004). Cancer Chemother Pharmacol 53: 116–122.
Majewski N, Nogueira V, Robey RB, Hay N . (2004). Mol Cell Biol 24: 730–740.
Marangos PJ, Parma AM, Goodwin FK . (1978). J Neurochem 31: 727–732.
Martin DS, Spriggs D, Koutcher JA . (2001). Apoptosis 6: 125–131.
Martin DS, Stolfi RL, Colofiore JR, Nord LD . (1996). Anticancer Drugs 7: 655–659.
Martin DS, Stolfi RL, Colofiore JR, Nord LD, Sternberg S . (1994). Cancer Invest 12: 296–307.
Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF et al. (2004). Cancer Res 64: 31–34.
Mathupala SP, Heese C, Pedersen PL . (1997a). J Biol Chem 272: 22776–22780.
Mathupala SP, Rempel A, Pedersen PL . (1997b). J Bioenerg Biomembr 29: 339–343.
Mazurek S, Boschek CB, Hugo F, Eigenbrodt E . (2005). Semin Cancer Biol 15: 300–308.
Munoz-Pinedo C, Ruiz-Ruiz C, Ruiz de Almodovar C, Palacios C, Lopez-Rivas A . (2003). J Biol Chem 278: 12759–12768.
Nabi IR, Watanabe H, Raz A . (1990). Cancer Res 50: 409–414.
Nagy E, Henics T, Eckert M, Miseta A, Lightowlers RN, Kellermayer M . (2000). Biochem Biophys Res Commun 275: 253–260.
Natali PG, Salsano F, Viora M, Nista A, Malorni W, Marolla A et al. (1984). Oncology 41: 7–14.
Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, et al., European-American Paraganglioma Study Group. (2004). J Am Med Assoc 292: 943–951.
Niederacher D, Entian KD . (1991). Eur J Biochem 200: 311–319.
Niinaka Y, Paku S, Haga A, Watanabe H, Raz A . (1998). Cancer Res 58: 2667–2674.
Niizeki H, Kobayashi M, Horiuchi I, Akakura N, Chen J, Wang J et al. (2002). Br J Cancer 86: 1914–1919.
Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF et al. (2003). J Neurooncol 63: 81–86.
Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E et al. (2003). J Clin Oncol 21: 3462–3468.
Pastorino JG, Hoek JB . (2003). Curr Med Chem 10: 1535–1551.
Pastorino JG, Shulga N, Hoek JB . (2002). J Biol Chem 277: 7610–7618.
Pawlu C, Bausch B, Hartmut PH . (2005). Familial Cancer 4: 49–54.
Pelicano H, Carney D, Huang P . (2004). Drug Resist Update 7: 97–110.
Penkowa M, Quintana A, Carrasco J, Giralt M, Molinero A, Hidalgo J . (2004). J Neurosci Res 77: 35–53.
Perucho M, Salas J, Salas ML . (1980). Biochim Biophys Acta 606: 181–195.
Pirinen E, Heikkinen S, Malkki M, Deeb SS, Janne J, Laakso M . (2004). Biochim Biophys Acta 1676: 149–154.
Pollard PJ, Wortham NC, Tomlinson IP . (2003). Ann Med 35: 632–639.
Rais B, Comin B, Puigjaner J, Brandes JL, Creppy E, Saboureau D et al. (1999). FEBS Lett 456: 113–118.
Ramanathan A, Wang C, Schreiber SL . (2005). Proc Natl Acad Sci USA 102: 5992–5997.
Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB . (2003). Mol Cell Biol 23: 7315–7328.
Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL . (1996). Cancer Res 56: 2468–2471.
Rodriguez A, De La Cera T, Herrero P, Moreno F . (2001). Biochem J 355: 625–631.
Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei III E . (1989). Cancer Chemother Pharmacol 25: 32–36.
Ruderman NB, Kapeller R, White MF, Cantley LC . (1990). Proc Natl Acad Sci USA 87: 1411–1415.
Seker H, Bertram B, Burkle A, Kaina B, Pohl J, Koepsell H et al. (2000). Br J Cancer 82: 629–634.
Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD et al. (2005). Cancer Cell 7: 77–85.
Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D et al. (2001). Novartis Found Symp 240: 251260.
Serkova N, Boros LG . (2005). Am J Pharmacogenomics 5: 293–302.
Shashidharan P, Chalmers-Redman RM, Carlile GW, Rodic V, Gurvich N, Yuen T et al. (1999). NeuroReport 10: 1149–1153.
Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL et al. (2005). Strahlenther Onkol 181: 507–514.
Singh KK . (2004). Ann NY Acad Sci 1019: 260–264.
Sirover MA . (2005). J Cell Biochem 95: 45–52.
Strumilo SA, Senkevich SB, Vinogradov VV . (1984). Biomed Biochim Acta 43: 159–163.
Sun YJ, Chou CC, Chen WS, Wu RT, Meng M, Hsiao CD . (1999). Proc Natl Acad Sci USA 96: 5412–5417.
Taguchi K, Takagi Y . (2001). Rinsh Byori 116: 117–124.
Tajima H, Tsuchiya K, Yamada M, Kondo K, Katsube N, Ishitani R . (1999). Neuro Report 10: 2029–2033.
Taylor RW, Turnbull DM . (2005). Nat Rev Genet 6: 389–402.
Tretter L, Adam-Vizi V . (2005). Philos Trans R Soc Lond B Biol Sci 360: 2335–2345.
VandeBerg JL . (1985). Isozymes Curr Top Biol Med Res 12: 133–187.
Van Schaftingen E, Hers HG . (1986). Eur J Biochem 159: 359–365.
Varshney R, Adhikari JS, Dwarakanath BS . (2003). Indian J Exp Biol 41: 1384–1391.
Varshney R, Dwarakanath B, Jain V . (2005). Int J Radiat Biol 81: 397–408.
Veyhl M, Wagner K, Volk C, Gorboulev V, Baumgarten K, Weber WM et al. (1998). Proc Natl Acad Sci USA 95: 2914–2919.
Vora S . (1983). Isozymes Curr Top Biol Med Res 11: 3–23.
Waltron RT, Rozengurt E . (2000). J Biol Chem 275: 17114–17121.
Warburg O . (1930). The Metabolism of Tumors. Costable: London.
Warburg O . (1956). Science 123: 309–314.
Warburg O, Posener K, Negelein E . (1924). Biochem Z 152: 309–344.
Watanabe H, Takehana K, Date M, Shinozaki T, Raz A . (1996). Cancer Res 56: 2960–2963.
Weindruch R, Keenan KP, Carney JM, Fernandes G, Feuers RJ, Floyd RA et al. (2001). J Gerontol A Biol Sci Med Sci 56: 20–33.
Williams KR, Reddigari S, Patel GL . (1985). Proc Natl Acad Sci USA 82: 5260–5264.
Wilson JE . (1995). Rev Physiol Biochem Pharmacol 126: 65–198.
Wilson JE . (2003). J Exp Biol 206: 2049–2057.
Xu LZ, Weber IT, Harrison RW, Gidh-Jain M, Pilkis SJ . (1995). Biochemistry 34: 6083–6092.
Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P . (2005a). Leukemia 19: 2153–2158.
Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN et al. (2005b). Cancer Res 65: 613–621.
Yoon DY, Buchler P, Saarikoski ST, Hines OJ, Reber HA, Hankinson O . (2001). Biochem Biophys Res Commun 288: 882–886.
Zhao YB, Yang HY, Zhang XW, Chen GY . (2005). World J Gastroenterol 11: 3304–3306.
Zheng L, Roeder RG, Luo Y . (2003). Cell 114: 255–266.
Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK . (1999). J Nutr 129: 1628–1635.
Zhu W, Qin W, Bradley P, Wessel A, Puckett CL, Sauter ER . (2005). Carcinogenesis 26: 145–152.
Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB . (2004). Genes Dev 18: 1272–1282.
Zu XL, Guppy M . (2004). Biochem Biophys Res Commun 313: 459–465.
Acknowledgements
This work was supported in part by grants CA085563, CA100428, and CA109041 from the National Cancer Institute, National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pelicano, H., Martin, D., Xu, RH. et al. Glycolysis inhibition for anticancer treatment. Oncogene 25, 4633–4646 (2006). https://doi.org/10.1038/sj.onc.1209597
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209597
Keywords
This article is cited by
-
Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations
Acta Neuropathologica Communications (2023)
-
Biomimetic nanovesicle co-delivery system impairs energy metabolism for cancer treatment
Journal of Nanobiotechnology (2023)
-
Aurora kinase A/AURKA functionally interacts with the mitochondrial ATP synthase to regulate energy metabolism and cell death
Cell Death Discovery (2023)
-
Notch signaling regulates a metabolic switch through inhibiting PGC-1α and mitochondrial biogenesis in dedifferentiated liposarcoma
Oncogene (2023)
-
To metabolomics and beyond: a technological portfolio to investigate cancer metabolism
Signal Transduction and Targeted Therapy (2023)